A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Mallinckrodt ARD LLC
- Target Recruit Count
- 44
- Registration Number
- NCT03400852
- Locations
- 🇲🇽
Neurociencias Estudios Clinicos S.C., Culiacán, Sinaloa, Mexico
🇪🇸Hospital de La Santa Creu i Sant Pau, Barcelona, Spain
🇪🇸Hospital Universitari i Politecnic La Fe Valencia, Valencia, Spain
Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)
Phase 4
Terminated
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- Mallinckrodt ARD LLC
- Target Recruit Count
- 35
- Registration Number
- NCT03126760
- Locations
- 🇺🇸
Neurology Associates, P. A., Maitland, Florida, United States
🇺🇸Wayne State University (WSU) - Multiple Sclerosis Treatment and Clinical Research Center (MS Center), Detroit, Michigan, United States
🇺🇸Neurology Center of San Antonio, San Antonio, Texas, United States
Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria
Phase 4
Completed
- Conditions
- Idiopathic Focal Segmental Glomerulosclerosis
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- Mallinckrodt ARD LLC
- Target Recruit Count
- 63
- Registration Number
- NCT02633046
- Locations
- 🇦🇺
Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
🇺🇸NKDHC Medical Research Services, LLC, Las Vegas, Nevada, United States
🇺🇸University of Cincinnati Physicians Company, LLC, Cincinnati, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath